The combination of ramucirumab and docetaxel prolonged progression-free survival over chemotherapy alone in patients with platinum-refractory advanced urothelial carcinoma, the first time in this setting that a regimen has improved outcomes over chemotherapy.
TRC105, a monoclonal antibody against endoglin, failed to improve progression-free survival when added to bevacizumab compared with bevacizumab alone in patients with refractory metastatic renal cell carcinoma.
More than half of patients with metastatic clear cell renal cell carcinoma treated with a combination of lenvatinib and pembrolizumab responded to treatment at week 24, according to interim results of a phase I/II study presented at the 2017 ESMO Congress.
The advantage with pembrolizumab has continued to improve, offering significantly better overall survival than chemotherapy in patients with recurrent, advanced urothelial carcinoma, according to the mature results of a phase III trial.
The first head-to-head comparison of docetaxel and abiraterone acetate for high-risk prostate cancer patients starting long-term hormone therapy found benefit with both treatments when added to ADT. Treatment decisions may come down to specific toxicities, which differ between the treatments.
An analysis that corrected for differences in implementation found that the two main trials of prostate cancer screening in Europe and the United States both show a reduction in prostate cancer mortality with screening.
Metastatic castration-resistant prostate cancer that has become resistant to docetaxel chemotherapy represents one of the greatest clinical challenges in the management of this disease.
African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients.
Immediate treatment with androgen-deprivation therapy for men with asymptomatic non-curable prostate cancer did not have major effects on quality of life compared with delayed use, according to a phase III trial.
Men with non-metastatic prostate cancer who receive androgen deprivation therapy risk loss of bone mineral density and fractures, but both bisphosphonates and denosumab can improve their bone health.
